Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- Drug Pricing Overhaul Must Strike Balance between Benefits and Costs: Health Insurance Bureau Chief
July 31, 2017
- Govt to Discuss Platforms to Promote Expansion of Drug Makers into Emerging Markets
July 31, 2017
- MHLW Advisory Panel Backs Approval of Pfizer’s Palbociclib
July 28, 2017
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
- Chuikyo Scrutiny Continues for Cost Calculation Pricing Formula
July 27, 2017
- Chuikyo Members at Odds over How to Proceed with “CEA” Debate
July 27, 2017
- Govt OKs Basic Policy for FY2018 Budget Requests
July 21, 2017
- Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS
July 20, 2017
- MHLW Panel to Discuss Zetia + Lipitor Combination Product on Aug. 1
July 20, 2017
- Shiozaki Says MHLW to Uphold 3-Year 1.5 Trillion Yen Cap in Social Security Cost Rise, CEFP Panelists Call for Further Curtailment
July 19, 2017
- Azithromycin under PMDA Risk Review for Acute Generalized Exanthematous Pustulosis
July 19, 2017
- MHLW to Take Strict Action on Bayer after Xarelto Survey Probe
July 19, 2017
- MHLW Panel Agrees to Compile Guidelines to Address Polypharmacy in the Elderly
July 18, 2017
- Gov’t Establishing System to Quickly Provide Unapproved Drugs to Developing Countries, Learning from Inadequate Response to Request for Avigan
July 18, 2017
- Pfizer’s Breast Cancer Med Palbociclib Up for MHLW Panel Review on July 27
July 14, 2017
- Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat
July 14, 2017
- MHLW Presents Draft Survey Sheet for “Willing-to-Pay” Costs in “CEA” Scheme: Chuikyo
July 13, 2017
- Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting
July 13, 2017
- Alminoprofen Reclassified as Class 1 OTC Drug: MHLW
July 13, 2017
- Osaka Prefecture to Conduct Surprise Onsite Inspections of API Manufacturing Facilities in Wake of Acetaminophen Scandal
July 13, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…